Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were male or non-pregnant females, 18 years of age or older, in generally good health. Females who were post-menopausal, surgically sterile or using a medically acceptable form of birth control with a negative urine pregnancy test at the Baseline visit.~* Subjects provided written and verbal informed consent.~* Subjects presented to the clinic with at least 4 but no more than 12 visible, discrete nonhyperkeratotic, nonhypertrophic actinic keratosis lesions within a 25 cm2 Treatment Area on the face and/or anterior scalp.~* Subjects were willing and able to comply with study instructions and return to the clinic for required visits.~Exclusion Criteria:~* Subjects who were lactating, or planning to become pregnant during the study.~* Subjects had hyperkeratotic, hypertrophic or large mat-like AKs within the 25 cm2 Treatment Area.~* Subjects who had the need or were planning to be exposed to artificial tanning devices or excessive sunlight during the trial.~* Subjects who were immunosuppressed (e.g., HIV, systemic malignancy, graft vs. host disease, etc.).~* Subjects who experienced an unsuccessful outcome from previous imiquimod therapy.~* Subjects with known hypersensitivity or previous allergic reaction to any of the active or inactive components of the study drugs.~* Within 2 months: Facial and/or Anterior Scalp: laser resurfacing, photodynamic therapy, chemical peels, dermabrasion, topical application of 5-FU, imiquimod, diclofenac sodium or other treatments for AK or photodamage.~* Subjects who used the following systemic, oral or topical therapies for the periods specified prior to entry into the study:~Within 2 days: Topicals of any kind to the selected Treatment Area. Within 2 weeks: Facial topical medications: corticosteroids, alpha- hydroxyacids (e.g., glycolic acid, lactic acid, etc. greater than 5%), beta-hydroxyacid (salicylic acid greater than 2%), urea - greater than 5% or prescription retinoids (e.g., tazarotene, adapalene, tretinoin) to the face and/or anterior scalp.~Within 2 weeks: Cryotherapy to lesions adjacent to or within the 25 cm2 Treatment Area.~Within 4 weeks: Systemic steroid therapy: chemotherapeutic agents, psoralens, immunotherapy, or retinoids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Generic Imiquimod (Type: ACTIVE_COMPARATOR): imiquimod cream, 5%
- Aldara™ (Type: ACTIVE_COMPARATOR): Aldara™ (imiquimod) cream, 5%
- Vehicle cream (Type: PLACEBO_COMPARATOR): Vehicle cream (Actavis)

Based on this trial design, predict the completion outcome and termination type (if applicable).